Other Events ·
Bioxytran reported encouraging clinical observations in the first patient treated with PLICID, an investigational…
BIXTBioxytran, Inc
Bioxytran reported encouraging clinical observations in the first patient treated with PLICID, an investigational galectin antagonist for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The patient received once-weekly intravenous injections and demonstrated improved finger function and walking ability without adverse events. Bioxytran plans to pursue further clinical evaluation of PLICID in a larger population. Bioxytran is a clinical-stage biotechnology company developing innovative therapies for viral diseases, inflammatory conditions, and cancer metastasis using an AI-driven carbohydrate design platform.